中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
Chinese Journal of Experimental Surgery
2015年
9期
2261-2263
,共3页
急性重度闭合性颅脑损伤%高迁移率族蛋白B1%肿瘤坏死因子-α%白细胞介素-6%格拉斯哥预后评分
急性重度閉閤性顱腦損傷%高遷移率族蛋白B1%腫瘤壞死因子-α%白細胞介素-6%格拉斯哥預後評分
급성중도폐합성로뇌손상%고천이솔족단백B1%종류배사인자-α%백세포개소-6%격랍사가예후평분
Acute severe craniocerebral injury%High mobility group protein box-1%Tumor necrosis factor-α%Interleukin-6%Glasgow outcome scale
目的 探讨亚低温治疗对急性重度闭合性颅脑损伤患者机体高迁移率族蛋白B1(HMGB1)水平的作用及其治疗价值.方法 选取2014至2015年我院收治的106例急性重度闭合性颅脑损伤患者,按照随机数表法随机分为亚低温治疗组(57例)和对照组(49例),比较两组患者入组后第1、3、5天血清HMGB1、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6和颅内压差异,以及3个月后患者格拉斯哥预后评分差异.结果 亚低温治疗组第1、3、5天血清HMGB1水平显著低于对照组[(4.81 ±1.83) ng/L比(5.52±1.68) ng/L,(6.74±2.15) ng/L比(8.22±2.47) ng/L,(5.32±1.73) ng/L比(7.56±2.08) ng/L,P＜0.05],亚低温治疗组第1、3、5天血清TNF-α水平显著低于对照组[(1.22 ±0.38) ng/L比(1.72±0.31) ng/L,(1.57±0.42) ng/L比(2.18±0.41) ng/L,(1.42±0.39)ng/L比(1.87±0.47) ng/L,P＜0.05],亚低温治疗组第1、3、5天血清IL-6水平显著低于对照组[(145.21±28.35) ng/L比(174.13±32.65)ng/L,(229.54±45.37)ng/L比(287.43±52.36) ng/L,(178.76±37.56) ng/L比(214.16±34.06) ng/L,P＜0.05],且亚低温治疗组患者第1、3、5天颅内压均较对照组低[(21.3±3.7) mmHg比(25.1±3.8) mmHg,(16.8±3.1)mmHg比(22.1±4.8)mmHg,(14.6±3.2) mmHg比(20.4±3.4) mmHg(1 mmHg =0.133 kPa),P＜0.05],治疗完成3个月后亚低温组患者整体预后优于对照组(P＜0.05).结论 亚低温治疗可能通过降低血清HMGB1和炎症水平达到治疗急性重度闭合性颅脑损伤患者的效果.
目的 探討亞低溫治療對急性重度閉閤性顱腦損傷患者機體高遷移率族蛋白B1(HMGB1)水平的作用及其治療價值.方法 選取2014至2015年我院收治的106例急性重度閉閤性顱腦損傷患者,按照隨機數錶法隨機分為亞低溫治療組(57例)和對照組(49例),比較兩組患者入組後第1、3、5天血清HMGB1、腫瘤壞死因子-α(TNF-α)、白細胞介素(IL)-6和顱內壓差異,以及3箇月後患者格拉斯哥預後評分差異.結果 亞低溫治療組第1、3、5天血清HMGB1水平顯著低于對照組[(4.81 ±1.83) ng/L比(5.52±1.68) ng/L,(6.74±2.15) ng/L比(8.22±2.47) ng/L,(5.32±1.73) ng/L比(7.56±2.08) ng/L,P＜0.05],亞低溫治療組第1、3、5天血清TNF-α水平顯著低于對照組[(1.22 ±0.38) ng/L比(1.72±0.31) ng/L,(1.57±0.42) ng/L比(2.18±0.41) ng/L,(1.42±0.39)ng/L比(1.87±0.47) ng/L,P＜0.05],亞低溫治療組第1、3、5天血清IL-6水平顯著低于對照組[(145.21±28.35) ng/L比(174.13±32.65)ng/L,(229.54±45.37)ng/L比(287.43±52.36) ng/L,(178.76±37.56) ng/L比(214.16±34.06) ng/L,P＜0.05],且亞低溫治療組患者第1、3、5天顱內壓均較對照組低[(21.3±3.7) mmHg比(25.1±3.8) mmHg,(16.8±3.1)mmHg比(22.1±4.8)mmHg,(14.6±3.2) mmHg比(20.4±3.4) mmHg(1 mmHg =0.133 kPa),P＜0.05],治療完成3箇月後亞低溫組患者整體預後優于對照組(P＜0.05).結論 亞低溫治療可能通過降低血清HMGB1和炎癥水平達到治療急性重度閉閤性顱腦損傷患者的效果.
목적 탐토아저온치료대급성중도폐합성로뇌손상환자궤체고천이솔족단백B1(HMGB1)수평적작용급기치료개치.방법 선취2014지2015년아원수치적106례급성중도폐합성로뇌손상환자,안조수궤수표법수궤분위아저온치료조(57례)화대조조(49례),비교량조환자입조후제1、3、5천혈청HMGB1、종류배사인자-α(TNF-α)、백세포개소(IL)-6화로내압차이,이급3개월후환자격랍사가예후평분차이.결과 아저온치료조제1、3、5천혈청HMGB1수평현저저우대조조[(4.81 ±1.83) ng/L비(5.52±1.68) ng/L,(6.74±2.15) ng/L비(8.22±2.47) ng/L,(5.32±1.73) ng/L비(7.56±2.08) ng/L,P＜0.05],아저온치료조제1、3、5천혈청TNF-α수평현저저우대조조[(1.22 ±0.38) ng/L비(1.72±0.31) ng/L,(1.57±0.42) ng/L비(2.18±0.41) ng/L,(1.42±0.39)ng/L비(1.87±0.47) ng/L,P＜0.05],아저온치료조제1、3、5천혈청IL-6수평현저저우대조조[(145.21±28.35) ng/L비(174.13±32.65)ng/L,(229.54±45.37)ng/L비(287.43±52.36) ng/L,(178.76±37.56) ng/L비(214.16±34.06) ng/L,P＜0.05],차아저온치료조환자제1、3、5천로내압균교대조조저[(21.3±3.7) mmHg비(25.1±3.8) mmHg,(16.8±3.1)mmHg비(22.1±4.8)mmHg,(14.6±3.2) mmHg비(20.4±3.4) mmHg(1 mmHg =0.133 kPa),P＜0.05],치료완성3개월후아저온조환자정체예후우우대조조(P＜0.05).결론 아저온치료가능통과강저혈청HMGB1화염증수평체도치료급성중도폐합성로뇌손상환자적효과.
Objective To investigate the effect of Hypothermia to high mobility group protein box-1 (HMGB1),inflammtory mediators and prognosis in acute severe craniocerebral injury patients.Methods Total 106 acute severe craniocerebral injury patients admitted between March 2014 to March 2015 were randomly divided into hypothermia group (57 cases) and control group (49 cases).Serum HMGB1,tumor necrosis factor-α (TNF-α),interleukin (IL)-6,intracranial pressure and Glasgow outcome scale were compared between hypothermia group and control group at the first,third and fifth day after treatment beginning.Results Serum HMGB1 were reduced in hypothermia group than control group atthe 1,3 and5day [(4.81 ±1.83) ng/Lvs.(5.52±1.68) ng/L,(6.74±2.15) ng/Lvs.(8.22± 2.47) ng/L,(5.32 ± 1.73) ng/L vs.(7.56 ± 2.08) ng/L,P ＜ 0.05,respectively].Serum TNF-α were reduced in hypothermia group than control group at the 1,3 and 5 day [(1.22 ± 0.38) ng/L vs.(1.72±0.31) ng/L,(1.57±0.42) ng/Lvs.(2.18±0.41) ng/L,(1.42±0.39) ng/L vs.(1.87± 0.47) ng/L,P＜0.05].Serum IL-6 were reduced in hypothermia group than control group at the 1,3 and5 day[(145.21 ±28.35) ng/L vs.(174.13 ±32.65) ng/L,(229.54 ±45.37) ng/L vs.(287.43 ± 52.36) ng/L,(178.76 ±37.56) ng/L vs.(214.16 ±34.06) ng/L,P ＜0.05].Introcranial pressure were reduced in hypothermia group than control group at the 1,3 and 5 day [(21.3 ± 3.7) mmHg vs.(25.1 ±3.8) mmHg,(16.8±3.1) mmHg vs.(22.1 ±4.8) mmHg,(14.6±3.2) mmHgvs.(20.4± 3.4) mmHg (1 mmHg =0.133 kPa),P ＜ 0.05].Prognosis of patients in hypothermia group were better than control group.Serum HMGB1,TNF-α,IL-6,intracranial pressure were reduced in hypothermia group than control group (P ＜ 0.05,respectively).Glasgow outcome scale was improved in hypothermia group than control group (P ＜ 0.05).Conclusion Hypothermia improved prognosis in acute severe craniocerebral injury patients by reduced serum HMGB1 and inflammatory mediators levels.
